Cover Image
Market Research Report
Product code 
1067372

Atopic Dermatitis - Epidemiology Analysis and Forecast, 2020-2030

Published: | GlobalData | 26 Pages | Delivery time: 1-2 business days

Price

Back to Top
Atopic Dermatitis - Epidemiology Analysis and Forecast, 2020-2030
Published: February 28, 2022
GlobalData
Content info: 26 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Although the condition affects people of all ages, it is primarily common among infants and children (Bowcock and Cookson, 2004). In general, the prevalence of AD is increasing worldwide, with high prevalence in Western and developed nations compared with other parts of the world. However, recent trends demonstrate a gradual rise in prevalence in developing countries and plateauing prevalence in developed countries (Asher et al., 2006). Although AD is not life-threatening, it has a huge impact on the patient's quality of life and causes a significant economic burden (Carroll et al., 2005).

GlobalData epidemiologists utilized nationally representative and country-specific peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the 12-month diagnosed prevalent cases of AD. For the 7MM, diagnosed prevalent cases of AD were segmented by age, sex, and severity.

GlobalData epidemiologists forecast that the 12-month diagnosed prevalent cases of AD in the 7MM will grow by an annual growth rate (AGR) of 0.03% over the next 10 years, from 42,138,193 cases in 2020 to 42,245,459 cases in 2030. Trends in the 7MM and specific markets can be attributed in part to changes in the underlying population structure. As atopic dermatitis is most frequently diagnosed in children and adolescents, the condition inflicts considerable psychosocial and economic burden on the families of the affected. More research is needed to understand the etiological factors associated with AD to take preventive measures and reduce these burdens.

Scope

  • The Atopic Dermatitis Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of Atopic Dermatitis (AD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the 12-month diagnosed prevalent cases of AD segmented by age (0-11, 12-17, 18-29 years, and by 10-year age groups up to 80 years and older), sex, and severity (mild, moderate, and severe). The epidemiology model accompanying this report also includes diagnosed prevalent cases of AD severity segmented by pediatric and adult population and total prevalent cases for all ages and both sexes combined.
  • The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The AD Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global AD markets.
  • Quantify patient populations in the global AD markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
  • Understand magnitude of the AD population by age, sex, and severity.
Product Code: GDHCER293-22

Table of Contents

Table of Contents

1 Atopic Dermatitis: Executive Summary

  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 7MM Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 12-Month Diagnosed Prevalent Cases of AD
    • 2.4.4 Forecast Assumptions and Methods: 12-Month Diagnosed Prevalent Cases of AD by Severity
  • 2.5 Epidemiological Forecast for Atopic Dermatitis (2020-30)
    • 2.5.1 12-Month Diagnosed Prevalent Cases of AD
    • 2.5.2 Age-Specific 12-Month Diagnosed Prevalent Cases of AD
    • 2.5.3 Sex-Specific 12-Month Diagnosed Prevalent Cases of AD
    • 2.5.4 12-Month Diagnosed Prevalent Cases of AD by Severity
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of the Analysis
    • 2.6.4 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us

List of Tables

List of Tables

  • Table 1: Summary of Updated Data Types
  • Table 2: Risk Factors and Comorbidities for AD

List of Figures

List of Figures

  • Figure 1: 7MM, 12-Month Diagnosed Prevalent Cases of Atopic Dermatitis (AD), Both Sexes, N, All Ages, 2020 and 2030
  • Figure 2: 7MM, Diagnosed Prevalence of AD, Men and Women, All Ages, %, 2020
  • Figure 3: 7MM, Sources Used and Not Used for the 12-Month Diagnosed Prevalent Cases of AD in the Adult Population
  • Figure 4: 7MM, Sources Used and Not Used for the 12-Month Diagnosed Prevalent Cases of AD in the Pediatric Population
  • Figure 5: 7MM, Sources Used for the 12-Month Diagnosed Prevalent Cases of AD by Severity in the Adult Population
  • Figure 6: 7MM, Sources Used for the 12-Month Diagnosed Prevalent Cases of AD by Severity in the Pediatric Population
  • Figure 7: 7MM, 12-Month Diagnosed Prevalent Cases of AD, N, Men and Women, All Ages, 2020
  • Figure 8: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of AD, N, Men and Women, 2020
  • Figure 9: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of AD, N, All Ages, 2020
  • Figure 10: 7MM, 12-Month Diagnosed Prevalent Cases of AD by Severity, Men and Women, N, All Ages, 2020